<![CDATA[ASCO Issues First Living Guideline for Recurrent Ovarian Cancer Treatment]]>

mirvetuximab soravtansinebevacizumabPositive

AI Analysis

Summary

ASCO released its first living guideline for recurrent ovarian cancer treatment, recommending platinum-based doublets, selective bevacizumab, and mirvetuximab soravtansine for FRα-positive platinum-resistant disease. This guideline endorsement supports treatment options for recurrent ovarian cancer patients.

Outcome Details

ASCO issued first living guideline for recurrent ovarian cancer treatment recommending platinum-based doublets, selective bevacizumab, and mirvetuximab soravtansine for FRα-positive platinum-resistant disease

Importance:6/10

Sentiment:

0.60

ovarian cancertreatment guidelineASCOmirvetuximab soravtansineFRα-positiveplatinum-resistantliving guideline

Related Companies

$ATALF $TRAX

Read the original article

Published by Cancer Network on August 30, 2026 4:00 PM

Read Original